Plasmid DNA Manufacturing: Strategies for Advanced Therapy Development
Dedicated to supporting developers as they navigate the complex path to clinic, and in response to increased demand, our integrated plasmid CDMO service offering has expanded to include a broader range of screening options, predictable platform manufacturing for phase-appropriate High Quality (HQ) and GMP grade plasmids, and an off-the-shelf plasmid product portfolio to reliably support viral vector manufacture, with 100% in-house testing for supply chain simplification.
This easily digestible 30-minute webinar reviews the role of plasmid DNA as a critical starting material, explores the latest advancements in associated regulatory guidance to safeguard therapeutic programs, and presents case studies to demonstrate expedited development and manufacture of advanced therapies.
Join Dr. Andrew Frazer to:
- Understand common manufacturing and quality standards for plasmid DNA and how they align with regulatory guidance
- Determine manufacturing strategies and mitigation plans to streamline your ATMP programs
- Explore case study examples
About the Presenters
Andrew Frazer, PhD
Associate Director, Scientific Solutions, Gene Therapy CDMO Services
Streamline your AAV-Based Gene Therapy Program
Reliable, ready-to-use Rep/Cap and Helper plasmid products designed to expedite production timelines by up to 66%.
Ready, Set, Go